OBJECTIVE To evaluate the therapeuticeffect and potential adverse ef- fects of sodium ibandronate(SI)in patients with malignant tumor ostealgia. METHODS Patients were randomly classified into two groups.Group A(SI)of 68 patients who received 4 mg SI i.v.,and 73 patients in Group B (pamidronate disodium[PD])who received 60 mg PD i.v.A randomized, double-blind method,with PD as a positive drug control,was used to assess changes in bone pain and adverse effects over a three-week period. RESULTS A total of 141 patients were enrol ed in the study,with 136 cases of appraisable efficacy.The effective rate was 72.3%(47/65)in Group A,and 63.4%(45/71)in Group B.There was no significant difference in ef- ficacy or adverse effects between the 2 groups. CONCLUSION The SI injection,with a pronounced effect,can relieve bone pain caused by osseous metastasis from a malignant tumor.The cura- tive and adverse effects were similar compared to PD. OBJECTIVE To evaluate the therapeutic? Effect and potential adverse ef- fects of sodium ibandronate (SI) in patients with malignant tumor ostealgia. METHODS Patients were randomly classified into two groups. Group A (SI) of 68 patients who received 4 mg SI iv, and 73 patients in Group B (pamidronate disodium [PD]) who received 60 mg PD ivA randomized, double-blind method, with PD as a positive drug control, was used to assess changes in bone pain and adverse effects over a three-week RESULTS. A total of 141 patients were enrolled in the study, with 136 cases of appraisable efficacy. The effective rate was 72.3% (47/65) in Group A, and 63.4% (45/71) in Group B. There was no significant difference in ef- ficacy or adverse effects between the 2 groups. CONCLUSION The SI injection, with a pronounced effect, can relieve bone pain caused by osseous metastasis from a malignant tumor. cura- tive and adverse effects were similar compared to PD.